Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis

Journal of Medicinal Chemistry

Volumn 58, Issue 11, 2015, Pages 4462-4482

  Tamayo, Nuria A ^a   Norman, Mark H ^a   Bartberger, Michael D ^a   Hong, Fang Tsao ^a   Bo, Yunxin ^a   Liu, Longbin ^a   Nishimura, Nobuko ^a   Yang, Kevin C ^a   Tadesse, Seifu ^a   Fotsch, Christopher ^a   Chen, Jie ^b   Chmait, Samer ^a   Cupples, Rod ^a   Hale, Clarence ^a   Jordan, Steven R ^a   Lloyd, David J ^a   Sivits, Glenn ^a   Van, Gwyneth ^b   St Jean, David J ^a  

^a Department of Therapeutic Discovery Medicinal Chemistry ^*  (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,1 TRIFLUORO 2 [4 [5 [(4 METHOXYBENZYL)THIO] 1 METHYL 1H IMIDAZOL 2 YL]PHENYL]PROPAN 2 OL; 1,1,1,3,3,3 HEXAFLUORO 2 [4 [4 [(4 METHOXYBENZYL)THIO] 1 METHYL 1H IMIDAZOL 2 YL]PHENYL]PROPAN 2 OL; 2 BROMO 4 [(4 METHOXYBENZYL)THIO] 1 METHYL 1H IMIDAZOLE; 2 [3 CHLORO 4 (THIAZOL 2 YL)PHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 2 [3 CHLORO 4 (THIAZOL 2 YL)PHENYL]PROPAN 2 OL; 2 [3 CHLORO 4 (THIAZOL 2 YL)PHENYL]PROPANE 1,2 DIOL; 2 [3 CHLORO 4 [5 [(6 CHLOROPYRIDIN 3 YL)THIO]THIAZOL 2 YL]PHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 2 [3 CHLORO 4 [5 [(6 CHLOROPYRIDIN 3 YL)THIO]THIAZOL 2 YL]PHENYL]PROPANE 1,2 DIOL; 2 [4 (4 BROMOTHIAZOL 2 YL)PHENYL] 1,1,1,3,3,3 HEXAFLUOROPROPAN 2 OL; 2 [4 (5 BROMO 1 METHYL 1H IMIDAZOL 2 YL)PHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 2 [4 (5 BROMOTHIAZOL 2 YL) 3 CHLOROPHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 2 [4 (5 BROMOTHIAZOL 2 YL) 3 CHLOROPHENYL]PROPAN 2 OL; 2 [4 (5 BROMOTHIAZOL 2 YL) 3 CHLOROPHENYL]PROPANE 1,2 DIOL; 2 [4 [4 [(6 AMINOPYRIDIN 3 YL)SULFONYL] 1 METHYL 1H IMIDAZOL 2YL]PHENYL] 1,1,1,3,3,3 HEXAFLUOROPROPAN 2 OL; 2 [4 [4 [(6 AMINOPYRIDIN 3 YL)SULFONYL]THIAZOL 2 YL]PHENYL] 1,1,1,3,3,3 HEXAFLUOROPROPAN 2 OL; 2 [4 [4 [(6 AMINOPYRIDIN 3 YL)THIO] 1 METHYL 1H IMIDAZOL 2 YL]PHENYL] 1,1,1,3,3,3 HEXAFLUOROPROPAN 2 OL; 2 [4 [4 [(6 CHLOROPYRIDIN 3 YL)THIO]THIAZOL 2 YL]PHENYL] 1,1,1,3,3,3 HEXAFLUOROPROPAN 2 OL; 2 [4 [5 [(6 AMINOPYRIDIN 3 YL)SULFONYL] 1 METHYL] 1H IMIDAZOL 2 YL]PHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 2 [4 [5 [(6 AMINOPYRIDIN 3 YL)SULFONYL]THIAZOL 2 YL] 3 CHLOROPHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 2 [4 [5 [(6 AMINOPYRIDIN 3 YL)SULFONYL]THIAZOL 2 YL] 3 CHLOROPHENYL]PROPANE 1,2 DIOL; 2 [4 [5 [(6 AMINOPYRIDIN 3 YL)THIO] 1 METHYL 1H IMIDAZOL 2 YL]PHENYL] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 CHLORO 4 (THIAZOL 2 YL)BENZENESULFONAMIDE; 3 CHLORO 4 [5 [(6 CHLOROPYRIDIN 3 YL)THIO]THIAZOL 2 YL]BENZENESULFONAMIDE; 4 (5 BROMOTHIAZOL 2 YL) 3 CHLOROBENZENESULFONAMIDE; 4 [5 [(6 AMINOPYRIDIN 3 YL)SULFONYL]THIAZOL 2 YL] 3 CHLOROBENZENESULFONAMIDE; GLUCOKINASE; GLUCOKINASE REGULATORY PROTEIN; REGULATOR PROTEIN; SULFONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2-(4-(5-((6-AMINOPYRIDIN-3-YL)SULFONYL)THIAZOL-2-YL)-3-CHLOROPHENYL)PROPANE-1,2-DIOL; AMINOPYRIDINE DERIVATIVE; ANTIDIABETIC AGENT; CARRIER PROTEIN; GLUCOSE; MOLECULAR LIBRARY;

ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; CYTOLOGY; DRUG EFFECTS; LIVER; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; RAT; SPRAGUE DAWLEY RAT; X RAY CRYSTALLOGRAPHY;

AMINOPYRIDINES; ANIMALS; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; GLUCOKINASE; GLUCOSE; HYPOGLYCEMIC AGENTS; LIVER; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 84935897406     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5018175     Document Type: Article

References (30)

1. Agius, L. Glucokinase and molecular aspects of liver glycogen metabolism Biochem. J. 2008, 414, 1 - 18
2. Matschinsky, F. M. Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes Diabetes 1990, 39, 647 - 652
3. Matschinsky, F. M.; Glaser, B.; Magnuson, M. A. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities Diabetes 1998, 47, 307 - 315
4. Sarabu, R.; Grimsby, J. Targeting glucokinase activation for the treatment of type 2 diabetes-a status review Curr. Opin. Drug Discovery Dev. 2005, 8, 631 - 637
5. Rees, M. G.; Gloyn, A. L. Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favor? Br. J. Pharmacol. 2013, 168, 335 - 338
6. Matschinsky, F. M. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol. Sci. 2013, 34, 90 - 99
7. Meininger, G. E.; Scott, R.; Alba, M.; Shentu, Y.; Luo, E.; Amin, H.; Davies, M. J.; Kaufman, K. D.; Goldstein, B. J. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes Diabetes Care 2011, 34, 2560 - 2566
8. Matschinsky, F. M.; Zelent, B.; Doliba, N.; Changhong, L.; Vanderkooi, J. M.; Naji, A.; Sarabu, R.; Grimsby, J. Glucokinase activators for diabetes therapy (May 2010 status report) Diabetes Care 2011, 34 (Suppl 2) S236 - S243
9. Lloyd, D. J.; St. Jean, D. J., Jr.; Kurzeja, R. J. M.; Wahl, R. C.; Michelsen, K.; Cupples, R.; Chen, M.; Wu, J.; Sivits, G.; Helmering, J.; Komorowski, R.; Ashton, K. S.; Pennington, L. D.; Fotsch, C. H.; Vazir, M.; Chen, K.; Chmait, S.; Zhang, J.; Liu, L.; Norman, M. H.; Andrews, K. A.; Bartberger, M. D.; Van, G.; Galbreath, E. J.; Vonderfecht, S. L.; Wang, M.; Jordan, S. R.; Véniant, M. M.; Hale, C. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors Nature 2013, 504, 437 - 440
10. Ashton, K. S.; Andrews, K. L.; Bryan, M. C.; Chen, J.; Chen, K.; Chen, M.; Chmait, S.; Croghan, M.; Cupples, R.; Fotsch, C.; Helmering, J.; Jordan, S. R.; Kurzeja, R. J. M.; Michelsen, K.; Pennington, L. D.; Poon, S. F.; Sivits, G.; Van, G.; Vonderfecht, S. L.; Wahl, R. C.; Zhang, J.; Lloyd, D. J.; Hale, C.; St. Jean, D. J., Jr. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept J. Med. Chem. 2014, 57, 309 - 324
11. St. Jean, D. J., Jr.; Ashton, K. S.; Bartberger, M. D.; Chen, J.; Chmait, S.; Cupples, R.; Galbreath, E.; Helmering, J.; Hong, F.-T.; Jordan, S. R.; Liu, L.; Kunz, R. K.; Michelsen, K.; Nishimura, N.; Pennington, L. D.; Poon, S. F.; Reid, D.; Sivits, G.; Stec, M. M.; Tadesse, S.; Tamayo, N.; Van, G.; Yang, K. C.; Zhang, J.; Norman, M. H.; Fotsch, C.; Lloyd, D. J.; Hale, C. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogs with improved pharmacokinetic profiles J. Med. Chem. 2014, 57, 325 - 338
12. Nishimura, N.; Norman, M. H.; Liu, L.; Yang, K. C.; Ashton, K. S.; Bartberger, M. D.; Chmait, S.; Chen, J.; Cupples, R.; Fotsch, C.; Helmering, J.; Jordan, S. R.; Kunz, R. K.; Pennington, L. D.; Poon, S. F.; Siegmund, A.; Sivits, G.; Lloyd, D. J.; Hale, C.; St. Jean, D. J., Jr. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N -arylsulfonamido- N ′-aryl-piperazine series J. Med. Chem. 2014, 57, 3094 - 3116
13. Hong, F.-T.; Norman, M. H.; Ashton, K. S.; Bartberger, M. D.; Chen, J.; Chmait, S.; Cupples, R.; Fotsch, C.; Jordan, S. R.; Lloyd, D. J.; Sivits, G.; Tadesse, S.; Hale, C.; St. Jean, D. J., Jr. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket J. Med. Chem. 2014, 57, 5949 - 5964
14. Generated with the PyMOL Molecular Graphics System, version 1.7.2.3 (Schrödinger, LLC).
15. hGKRP-biotin was incubated with compound prior to addition of fluorescein-hGK and AlphaScreen beads (PerkinElmer). hGK-hGKRP binding was detected with Alphascreen fluorescein-detection beads in an EnVision Instrument (PerkinElmer).
16. Johansson, M. P.; Olsen, J. Torsional barriers and equilibrium angle of biphenyl: reconciling theory with experiment J. Chem. Theory Comput. 2008, 4, 1460 - 1471
17. Kwong, F. Y.; Buchwald, S. L. A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols Org. Lett. 2002, 4, 3517 - 3520
18. See the Supporting Information for synthesis of these compounds.
19. Guram, A. S.; Wang, X.; Bunel, E. E.; Faul, M. M.; Larsen, R. D.; Martinelli, M. J. New catalysts for Suzuki-Miyaura coupling reactions of heteroatom-substituted heteroaryl chlorides J. Org. Chem. 2007, 72, 5104 - 5112
20. Fernandez-Rodriguez, M. A.; Shen, Q.; Hartwig, J. F. A general and long-lived catalyst for the palladium-catalyzed coupling of aryl halides with thiols J. Am. Chem. Soc. 2006, 128, 2180 - 2181
21. Corey, E. J.; Chaykovsky, M. Dimethyloxosulfonium methylide ((CH3)2SOCH2) and dimethylsulfonium methylide ((CH3)2SCH2). Formation and application to organic synthesis J. Am. Chem. Soc. 1965, 87, 1353 - 1364
22. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, revision D.01; Gaussian, Inc.: Wallingford, CT, 2009.
23. Achiral bis-trifluoromethyl and racemic methyl-trifluoromethyl carbinols have been established to be generally equipotent and are indistinctly used thorough our SAR discussions.
24. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615 - 2623
25. Yu, J. Y.; Yoo, C. L.; Yang, B.; Lodewyk, M. W.; Meng, L.; El-Idreesy, T. T.; Fettinger, J. C.; Tantillo, D. J.; Verkman, A. S.; Kurth, M. J. Potent s-cis-locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy J. Med. Chem. 2008, 51, 6044 - 6054
26. Lin, S.; Wrobleski, S. T.; Hynes, J., Jr.; Pitt, S.; Zhang, R.; Fan, Y.; Doweyko, A. M.; Kish, K. F.; Sack, J. S.; Malley, M. F.; Kiefer, S. E.; Newitt, J. A.; McKinnon, M.; Trzaskos, J.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 5864 - 5868
27. Gökce, H.; Bahçeli, S. Analysis of molecular structure and vibrational spectra of 2-(2′-thienyl)pyridine J. Mol. Struct. 2011, 1005, 100 - 106
28. Note the higher-lying (ca. 0.7 kcal/mol) undesired local minimum of the thiazole analog resides at a dihedral angle of ∼140, not 180, due to N-Cl repulsion.
29. Stereochemistry arbitrarily assigned.
30. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997 - 10002